Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

126,805 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and safety of vorolanib plus everolimus in metastatic renal cell carcinoma: A three-arm, randomised, double-blind, multicentre phase III study (CONCEPT).
Sheng X, Ye D, Zhou A, Yao X, Luo H, He Z, Wang Z, Zhao Y, Ji Z, Zou Q, He C, Guo J, Tu X, Liu Z, Shi B, Liu B, Chen P, Wei Q, Hu Z, Zhang Y, Jiang K, Zhou F, Wu D, Fu C, Li X, Wu B, Wang L, Qin S, Li G, Liu Y, Guo H, Chen K, Zhang D, Wang G, Ding L, Wang Y, Yuan X, Guo J. Sheng X, et al. Among authors: wang g, wang l, wang z, wang y. Eur J Cancer. 2023 Jan;178:205-215. doi: 10.1016/j.ejca.2022.10.025. Epub 2022 Nov 1. Eur J Cancer. 2023. PMID: 36459768 Free article. Clinical Trial.
Efficacy and Safety of Serenoa repens Extract Among Patients with Benign Prostatic Hyperplasia in China: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial.
Ye Z, Huang J, Zhou L, Chen S, Wang Z, Ma L, Wang D, Wang G, Wang S, Liang C, Qiu S, Gu X, Liu J, Weng Z, Wu C, Wei Q, Xie L, Wu W, Cheng Y, Hu J, Wang Z, Zeng X. Ye Z, et al. Among authors: wang g, wang z, wang d, wang s. Urology. 2019 Jul;129:172-179. doi: 10.1016/j.urology.2019.02.030. Epub 2019 Mar 14. Urology. 2019. PMID: 30880074 Clinical Trial.
Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial.
Gu C, Wang Z, Lin T, Liu Z, Han W, Zhang X, Liang C, Liu H, Yu Y, Xu Z, Liu S, Wang J, Jia L, Yao X, Liao W, Fu C, Tan Z, He G, Zhu G, Fan R, Yang W, Chen X, Liu Z, Zhong L, Shi B, Ding D, Chen S, Wei J, Yao X, Chen M, Lu Z, Xie Q, Hu Z, Wang Y, Guo H, Fan T, Liang Z, Chen P, Wang W, Xu T, Li C, Xing J, Liao H, He D, Wu Z, Yu J, Feng Z, Yang M, Dou Q, Zeng Q, Li Y, Gou X, Zhou G, Wang X, Zhu R, Zhang Z, Zhang B, Tan W, Qu X, Sun H, Gan T, Ye D. Gu C, et al. Among authors: wang x, wang w, wang z, wang j, wang y. Chin Med J (Engl). 2023 May 20;136(10):1207-1215. doi: 10.1097/CM9.0000000000002638. Epub 2023 Apr 3. Chin Med J (Engl). 2023. PMID: 37010251 Free PMC article. Clinical Trial.
Real-world effectiveness and safety of goserelin 10.8-mg depot in Chinese patients with localized or locally advanced prostate cancer.
Chen N, Wang Z, Chen M, Ma Q, He Y, Wang Y, Li X, Qiu M, Shi L, Zhu S, Xie Q, Liu X, Shi B, Lin G, Yang W, Liao Y, Zhang H, Wang S, Li J, Wang S, Dong L, Chen H, Lu J, Cheng Y, Zhang X, Ma L, Zhou L, Wang H, Li S, Ye D. Chen N, et al. Among authors: wang h, wang z, wang y, wang s. Cancer Biol Med. 2024 Feb 5;20(12):1047-59. doi: 10.20892/j.issn.2095-3941.2023.0335. Cancer Biol Med. 2024. PMID: 38318809 Free PMC article.
126,805 results
You have reached the last available page of results. Please see the User Guide for more information.